Investor service announcement no. 1/2012
To: NASDAQ OMX Copenhagen Hørsholm, Denmark, 17 August, 2012
Veloxis Pharmaceuticals A/S to Host Conference Call Announcing Interim Report for second Quarter 2012 – results from 1 January to 30 June, 2012
Veloxis Pharmaceuticals A/S (OMX: VELO) will announce the Interim Report for the second Quarter 2012 on Wednesday 22 August, 2012 after 05:00 PM. Veloxis’ Management will host an accompanying conference call to discuss the financial results on Thursday 23 August, 2012 at 08:00 AM CET (Denmark); 07:00 AM GMT (London).
To access the live conference call, please dial one of the following numbers:
+45 32 72 76 25 Denmark Local
+1 631 510 7498 USA Local
+44 (0)1452 555 566 UK Local
Conference ID: 21465742
An audio cast of the conference will be available on www.veloxis.com.
For more information, please contact:
|
John Weinberg, M.D. Chief Commercial Officer Phone: +1 908 304 3389 Email: jdw@veloxis.com |
Johnny Stilou Chief Financial Officer Phone: +45 21 227 227 Email: jst@veloxis.com |
Veloxis Pharmaceuticals A/S (VELO)
Based in Hørsholm, Denmark, with an office in New Jersey, Veloxis Pharmaceuticals A/S, or Veloxis, is a specialty pharmaceutical company. The company’s lead product candidate is LCP‐Tacro™ for immunosuppression, specifically organ transplantation. Veloxis’ unique, patented delivery technology, MeltDose®, can improve absorption and bioavailability at low-scale up costs. Veloxis has a lipid lowering product, Fenoglide®, currently on the U.S. market that is commercialized through partner Santarus, Inc.. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.
For further information, please visit www.veloxis.com.
